Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1
about
Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 PocketGenetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases.Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).Proteins, peptides, polysaccharides, and nucleotides with inhibitory activity on human immunodeficiency virus and its enzymes.Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity.Modular assembly of dimeric HIV fusion inhibitor peptides with enhanced antiviral potency.An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors.The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.Exceptional Potency and Structural Basis of a T1249-Derived Lipopeptide Fusion Inhibitor against HIV-1, HIV-2, and Simian Immunodeficiency Virus.Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus
P2860
Q33713101-5AD609A8-2D4C-4282-BC32-7A144ABBB0B2Q35641194-E5D8683D-E6E8-4409-84C8-1E4134F8BBE5Q36334376-11633555-89A2-4DD5-8E24-ED7242D44D44Q37512840-3698A768-C374-4C96-95E9-20772E47B768Q37512905-027967E3-CDB8-43E9-8118-F612EEE69CC2Q38261556-BB8E6EEC-B976-4FC5-92C1-06ADE45A6C05Q38271873-A4EF9878-2CA3-4427-9761-4BB69501420AQ38593985-8B12E67C-DBB9-4213-98B6-B160B6CE5D44Q40141950-9EFB7A38-4281-4F71-8C94-1D11ADED09ABQ40267838-222847E4-5295-4083-B006-CEA2D81DFAA9Q41841736-8EFE9EEA-EED1-4419-804E-2E74E654017DQ42050970-C5380C40-4E32-4244-8CDB-7E2B43929124Q42213760-C68700BE-5914-435B-B7EB-B35D25A6FE38Q50099962-014E9799-6004-42B7-A6B2-488EBF529EEFQ52656996-702D5C13-9889-4F71-8664-762B16F6083BQ57469894-6E0C551E-D6E7-43FA-A3EC-5C2CCCD62848
P2860
Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Short-peptide fusion inhibitor ...... nd enfuvirtide-resistant HIV-1
@ast
Short-peptide fusion inhibitor ...... nd enfuvirtide-resistant HIV-1
@en
Short-peptide fusion inhibitor ...... nd enfuvirtide-resistant HIV-1
@nl
type
label
Short-peptide fusion inhibitor ...... nd enfuvirtide-resistant HIV-1
@ast
Short-peptide fusion inhibitor ...... nd enfuvirtide-resistant HIV-1
@en
Short-peptide fusion inhibitor ...... nd enfuvirtide-resistant HIV-1
@nl
prefLabel
Short-peptide fusion inhibitor ...... nd enfuvirtide-resistant HIV-1
@ast
Short-peptide fusion inhibitor ...... nd enfuvirtide-resistant HIV-1
@en
Short-peptide fusion inhibitor ...... nd enfuvirtide-resistant HIV-1
@nl
P2093
P356
P1433
P1476
Short-peptide fusion inhibitor ...... nd enfuvirtide-resistant HIV-1
@en
P2093
Huihui Chong
Jianping Sun
Meitian Wang
Meng Zhang
Sandro Waltersperger
Zonglin Qiu
P304
P356
10.1096/FJ.12-222547
P407
P577
2012-12-11T00:00:00Z